{"commentary":{"count":74,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":33,"youtube":26,"podcast":14,"x_video":1},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05840211\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"ASCENT-07","nct_id":"NCT05840211","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=ascent-07-nct05840211. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources"},"registry":{"acronym":"ASCENT-07","arms":[{"description":"Participants will receive SG at a dose of 10 mg/kg infusion on Days 1 and 8 of a 21-day cycle.","label":"Sacituzumab Govitecan-hziy (SG)","type":"EXPERIMENTAL"},{"description":"Participants will receive TPC determined prior to randomization to 1 of the 3 allowed regimens:\n\n* paclitaxel 80 mg/m\\^2 over 1 hour (± 10 minutes) on Days 1, 8, and 15 of a 28-day cycle.\n* nab-Paclitaxel 100 mg/m\\^2 over 30 minutes (± 10 minutes) on Days 1, 8, and 15 of a 28-day cycle.\n* capecitabine at 1000-1250 mg/m\\^2 twice daily for 2 weeks followed by a 1-week rest period of a 21-day cycle.","label":"Treatment of Physician's Choice (TPC)","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2028-04","type":"ESTIMATED"},"conditions":["Locally Advanced or Unresectable Metastatic Breast Cancer","Stage IV Breast Cancer"],"enrollment":{"count":654,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Sacituzumab Govitecan-hziy","type":"DRUG"},{"name":"Paclitaxel","type":"DRUG"},{"name":"Nab-paclitaxel","type":"DRUG"},{"name":"Capecitabine","type":"DRUG"}],"last_update":"2025-10-03","lead_sponsor":"Gilead Sciences","official_title":"A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) (HER2 IHC0 or HER2-low [IHC 1+, IHC 2+/ISH-]) Inoperable, Locally Advanced, or Metastatic Breast Cancer and Have Received Endocrine Therapy","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2028-04","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Progression Free Survival (PFS) as Assessed by Blinded Independent Central Review (BICR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)","timeFrame":"Up to approximately 29 months"}],"references":[{"citation":"Tarantino P, Tolaney SM, Curigliano G. Trastuzumab deruxtecan (T-DXd) in HER2-low metastatic breast cancer treatment. Ann Oncol. 2023 Oct;34(10):949-950. doi: 10.1016/j.annonc.2023.07.003. Epub 2023 Jul 26. No abstract available.","pmid":"37499870","type":"DERIVED"}],"start_date":{"date":"2023-05-08","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy","url":"https://clinicaltrials.gov/study/NCT05840211"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/ascent-07-nct05840211"}